-$0.29 Earnings Per Share Expected for American Renal Associates Holdings Inc (NYSE:ARA) This Quarter

Analysts expect American Renal Associates Holdings Inc (NYSE:ARA) to report ($0.29) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for American Renal Associates’ earnings, with estimates ranging from ($0.39) to ($0.19). The firm is expected to issue its next quarterly earnings report on Monday, June 15th.

According to Zacks, analysts expect that American Renal Associates will report full-year earnings of ($0.50) per share for the current financial year, with EPS estimates ranging from ($0.71) to ($0.28). For the next fiscal year, analysts expect that the business will report earnings of ($0.30) per share, with EPS estimates ranging from ($0.42) to ($0.17). Zacks’ EPS calculations are an average based on a survey of research analysts that cover American Renal Associates.

American Renal Associates (NYSE:ARA) last announced its quarterly earnings results on Monday, March 16th. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.32. The firm had revenue of $206.08 million for the quarter, compared to analysts’ expectations of $217.42 million. American Renal Associates had a negative net margin of 2.54% and a positive return on equity of 19.63%.

Several research analysts have recently weighed in on the stock. Deutsche Bank assumed coverage on shares of American Renal Associates in a research report on Friday, January 3rd. They set a “hold” rating and a $12.00 price target on the stock. Zacks Investment Research cut shares of American Renal Associates from a “hold” rating to a “sell” rating in a research report on Monday, January 6th. ValuEngine cut shares of American Renal Associates from a “buy” rating to a “hold” rating in a research report on Tuesday, March 17th. Finally, SunTrust Banks boosted their price target on shares of American Renal Associates from $9.00 to $11.00 and gave the company a “hold” rating in a research report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating and four have issued a hold rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $10.00.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Citigroup Inc. lifted its position in American Renal Associates by 34.0% in the fourth quarter. Citigroup Inc. now owns 6,879 shares of the company’s stock valued at $71,000 after buying an additional 1,744 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in American Renal Associates by 347.3% in the third quarter. Tower Research Capital LLC TRC now owns 8,705 shares of the company’s stock valued at $55,000 after buying an additional 6,759 shares during the last quarter. Jefferies Group LLC acquired a new position in American Renal Associates in the fourth quarter valued at about $106,000. Dynamic Technology Lab Private Ltd acquired a new position in American Renal Associates in the fourth quarter valued at about $115,000. Finally, AQR Capital Management LLC acquired a new position in American Renal Associates in the fourth quarter valued at about $122,000. 84.02% of the stock is currently owned by institutional investors.

Shares of ARA stock traded up $0.31 on Monday, hitting $8.19. 109,800 shares of the stock traded hands, compared to its average volume of 94,419. The firm’s 50-day moving average price is $8.37 and its two-hundred day moving average price is $8.67. The company has a debt-to-equity ratio of 7.96, a quick ratio of 1.11 and a current ratio of 1.15. The stock has a market capitalization of $265.62 million, a PE ratio of 31.50 and a beta of 2.02. American Renal Associates has a twelve month low of $5.48 and a twelve month high of $13.80.

American Renal Associates Company Profile

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

See Also: Total Return

Get a free copy of the Zacks research report on American Renal Associates (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.